Skip to main content
Premium Trial:

Request an Annual Quote

NCI Joins Forces with AxCell Biosciences To Investigate Protein Phosphorylation

Premium

National Cancer Institute researchers have teamed up with AxCell Biosciences to study how two families of proteins participate in signal transduction pathways, AxCell said Oct. 10.

The collaboration, which is still in preliminary stages, will employ AxCell’s technology for studying interactions between certain proteins and peptide sequences, and investigate the roles of two protein families, the serine-threonine and tyrosine kinases, in signal transduction.

These two families of proteins are important in signal transduction because they add phosphate groups, or phosphorylate, other proteins, creating a cascade of phosphorylation events that carry messages within the cell. The NCI researchers, led by immunologist Steven Shaw, are hoping to learn what sites on a protein are susceptible to phosphorylation as a means of determining which proteins in the human proteome participate in signal transduction.

John Rodwell, president and chief technical officer of AxCell, said the two groups got together after an NCI manager heard an AxCell presentation at a recent conference. The AxCell researchers had not yet studied phosphorylation in proteins, but the company’s technology offered a comprehensive way of studying the mechanism of phosphorylation, Shaw told ProteoMonitor.

“It is essential to go about this systematically, rather than piecemeal as has been the norm in most labs in the past,” he said. “They have put together a set of infrastructure, patents, and informatics that allow them to be quite efficient in isolating domains, synthesizing peptides, and looking at the interactions between them.”

Specifically, the two groups of scientists will use AxCell’s technology to synthesize specific peptide sequences that resemble fragments or proteins, or individual protein folds, Shaw said. Using an in vitro kinase assay, the researchers will investigate which peptide sequences the kinases phosphorylate with a radio-labeled phosphate group.

“We’re working with Steve [Shaw] to predict what should be good substrates for these various kinases, we’re synthesizing them, and then we’re seeing if they do in fact behave as good substrates,” said Rodwell. “We study where these sequences occur in the human proteome, and that gives us a handle on what protein that particular kinase is acting on, and we can begin to build pathways on that basis.”

Although the AxCell technology is based on an in vitro technique — in contrast to in vivo methods for studying protein interactions, such as yeast two-hybrid — Rodwell said that he has validated many of the interactions with other data. “Yeast two-hybrid is a nice system if [you’re studying] a specific pathway, but we’re taking a much more systems approach to study multiple pathways at the same time,” he said.

Much of the data that the researchers generate will go towards populating AxCell’s ProChart database of protein interaction information, Rodwell said. AxCell is currently working with InforMax to integrate the ProChart database into InforMax’s GenoMax bioinformatics platform.

Rodwell and Shaw said they are still working out the details of the collaboration, and have not yet signed a letter of intent, but that they expect the deal to go forward.

— JSM

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.